KRAS and neoplasm: The tumor positive for a KRAS G12D mutation also harbored a known activating GNAQ R183Q mutation, albeit at varying allelic frequencies (KRAS G12D at 6%, GNAQ R183Q at 30%), suggesting that the sample may be heterogeneous and that the KRAS mutant allele may be present in a sub-clone.